New pill aims to prevent fat spike after Weight-Loss drug stop
NCT ID NCT06640972
First seen Jan 06, 2026 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This study tested a drug called RDX-002 in 68 adults who had recently stopped taking popular weight-loss medications like semaglutide or tirzepatide. The goal was to see if RDX-002 could lower high blood fats (triglycerides) after a fatty meal and help control weight. Participants took either RDX-002 or a placebo daily for 12 weeks, with clinic visits every 4 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLESTEROL, ELEVATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network
Saint Paul, Minnesota, 55114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RDX-002 (a gut-specific drug that blocks fat absorption)
What this could lead to
If it works, RDX-002 could help manage high triglycerides and weight regain after stopping GLP-1 weight-loss medications.
What could go wrong
This is a small, early-phase trial with only 68 people. The drug may not work better than placebo, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.